Pandora Wealth Inc. Buys New Position in Pulse Biosciences, Inc (NASDAQ:PLSE)

Key Points

• Pandora Wealth Inc. acquired a new stake in Pulse Biosciences, purchasing 51,452 shares valued at approximately $828,000.
• Oppenheimer initiated coverage on Pulse Biosciences, setting an "outperform" rating with a target price of $22.00 per share.
• The company's shares opened at $14.71, with a 52-week low of $13.77 and a high of $25.00.

Pandora Wealth Inc. purchased a new position in Pulse Biosciences, Inc (NASDAQ:PLSE - Free Report) during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 51,452 shares of the company's stock, valued at approximately $828,000. Pandora Wealth Inc. owned about 0.08% of Pulse Biosciences at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in PLSE. Tower Research Capital LLC TRC lifted its position in Pulse Biosciences by 98.1% during the 4th quarter. Tower Research Capital LLC TRC now owns 1,692 shares of the company's stock worth $29,000 after acquiring an additional 838 shares in the last quarter. KLP Kapitalforvaltning AS acquired a new position in Pulse Biosciences during the 4th quarter worth approximately $44,000. PNC Financial Services Group Inc. acquired a new position in Pulse Biosciences during the 1st quarter worth approximately $90,000. GAMMA Investing LLC lifted its position in Pulse Biosciences by 2,203.1% during the 1st quarter. GAMMA Investing LLC now owns 6,034 shares of the company's stock worth $97,000 after acquiring an additional 5,772 shares in the last quarter. Finally, Farther Finance Advisors LLC lifted its position in Pulse Biosciences by 24.6% during the 1st quarter. Farther Finance Advisors LLC now owns 8,998 shares of the company's stock worth $143,000 after acquiring an additional 1,778 shares in the last quarter. 76.95% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Separately, Oppenheimer started coverage on Pulse Biosciences in a report on Monday, July 7th. They set an "outperform" rating and a $22.00 price objective on the stock.

Insider Activity

In related news, CTO Darrin Uecker sold 15,000 shares of the company's stock in a transaction on Thursday, June 12th. The stock was sold at an average price of $16.40, for a total transaction of $246,000.00. Following the transaction, the chief technology officer directly owned 137,872 shares of the company's stock, valued at approximately $2,261,100.80. The trade was a 9.81% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 71.50% of the stock is owned by company insiders.

Pulse Biosciences Trading Up 10.9%

Shares of Pulse Biosciences stock traded up $1.65 during trading on Wednesday, hitting $16.75. The stock had a trading volume of 239,773 shares, compared to its average volume of 171,917. The business has a fifty day moving average of $15.48 and a two-hundred day moving average of $16.99. Pulse Biosciences, Inc has a fifty-two week low of $13.77 and a fifty-two week high of $25.00.

Pulse Biosciences Company Profile

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.